Hadjkacem I, Ayadi H, Turki M, Yaich S, Khemekhem K, Walha A, et al
Measurement of the activity of glutathione reductase, with and without the prosthetic group FAD, is the best method for assessing tissue riboflavin status, particularly in cases of impaired riboflavin status
Okay, we need to assert that that is a truth
Body as a Whole-General Disorders Asthenia 4 6 Leg Pain 2 3 Chest Pain 1 2 Central & Peripheral Nervous System Disorders Paresthesia 21 40 Dizziness 13 14 Hypoaesthesia 4 5 Ataxia 3 4 Hypertonia 0 3 Gastro-Intestinal System Disorders Diarrhea 5 6 Constipation 1 4 Gastritis 0 3 Dry Mouth 1 3 Gastroesophageal Reflux 1 2 Liver and Biliary System Disorders Gamma-GT Increased 1 3 Metabolic and Nutritional Disorders Weight Decrease 6 16 Psychiatric Disorders Somnolence 9 15 Anorexia 4 14 Difficulty with Memory NOS 5 10 Insomnia 8 9 Depression 7 9 Difficulty with Concentration/Attention 7 8 Anxiety 4 6 Psychomotor Slowing 3 5 Mood Problems 2 5 Confusion 3 4 Cognitive Problem NOS 1 4 Libido Decreased 0 3 Reproductive Disorders, Female Vaginal Hemorrhage 0 3 Red Blood Cell Disorders Anemia 1 2 Resistance Mechanism Disorders Infection Viral 6 8 Infection 2 3 Respiratory System Disorders Bronchitis 3 4 Rhinitis 2 4 Dyspnea 1 2 Skin and Appendages Disorders Rash 1 4 Pruritus 1 4 Acne 2 3 Special Senses Other, Disorders Taste Perversion 3 5 Urinary System Disorders Cystitis 1 3 Renal Calculus 0 3 Urinary Tract Infection 1 2 Dysuria 0 2 Micturition Frequency 0 2 Table 6: Incidence of Treatment-Emergent Adverse Events in the Monotherapy Epilepsy Trial in Children Ages 10 up to 16 Yearsa Where Rate Was at Least 5% in the 400 mg/day Topiramate Group and Greater Than the Rate in the 50 mg/day Topiramate Group Topiramate Dosage (mg/day) Body System/ Adverse Event 50 (N=57) 400 (N=57) a Values represent the percentage of patients reporting a given adverse event
Weinhaus et al., 2025)
Science2011 Jun 17;332(6036):1433-5
